281 related articles for article (PubMed ID: 22521633)
21. Application of LC-MS(n) in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance.
Li M; Lin M; Rustum A
J Pharm Biomed Anal; 2008 Dec; 48(5):1451-6. PubMed ID: 18977106
[TBL] [Abstract][Full Text] [Related]
22. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
[TBL] [Abstract][Full Text] [Related]
23. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
Karthikeyan K; Arularasu GT; Murali V; Pillai KC
J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
[TBL] [Abstract][Full Text] [Related]
24. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
Elder DP; Lipczynski AM; Teasdale A
J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
[TBL] [Abstract][Full Text] [Related]
25. Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.
Ramulu K; Kumar TT; Krishna SR; Vasudev R; Kaviraj M; Rao BM; Rao NS
Pharmazie; 2010 Mar; 65(3):162-8. PubMed ID: 20383934
[TBL] [Abstract][Full Text] [Related]
26. The application of gas chromatography/atmospheric pressure chemical ionisation time-of-flight mass spectrometry to impurity identification in Pharmaceutical Development.
Bristow T; Harrison M; Sims M
Rapid Commun Mass Spectrom; 2010 Jun; 24(11):1673-81. PubMed ID: 20486265
[TBL] [Abstract][Full Text] [Related]
27. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
[TBL] [Abstract][Full Text] [Related]
28. On-line H/D exchange LC-MS strategy for structural elucidation of pharmaceutical impurities.
Liu DQ; Wu L; Sun M; MacGregor PA
J Pharm Biomed Anal; 2007 Jun; 44(2):320-9. PubMed ID: 17317074
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
[TBL] [Abstract][Full Text] [Related]
30. Online hyphenated liquid chromatography-nuclear magnetic resonance spectroscopy-mass spectrometry for drug metabolite and nature product analysis.
Yang Z
J Pharm Biomed Anal; 2006 Feb; 40(3):516-27. PubMed ID: 16280226
[TBL] [Abstract][Full Text] [Related]
31. Major degradation product identified in several pharmaceutical formulations against the common cold.
Marín A; Espada A; Vidal P; Barbas C
Anal Chem; 2005 Jan; 77(2):471-7. PubMed ID: 15649042
[TBL] [Abstract][Full Text] [Related]
32. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
Thomas S; Mathela CS; Agarwal A; Paul SK
J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
[TBL] [Abstract][Full Text] [Related]
33. Detection, identification and quantification of a new de-fluorinated impurity in casopitant mesylate drug substance during late phase development: an analytical challenge involving a multidisciplinary approach.
Turco L; Provera S; Curcuruto O; Bernabè E; Nicoletti A; Martini L; Castoldi D; Cimarosti Z; Papini D; Marchioro C; Dams R
J Pharm Biomed Anal; 2011 Jan; 54(1):67-73. PubMed ID: 20813481
[TBL] [Abstract][Full Text] [Related]
34. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR.
Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
Anal Bioanal Chem; 2012 Nov; 404(8):2203-22. PubMed ID: 22986987
[TBL] [Abstract][Full Text] [Related]
35. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
Lalitha Devi M; Chandrasekhar KB
J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
[TBL] [Abstract][Full Text] [Related]
36. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
37. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
[TBL] [Abstract][Full Text] [Related]
38. Identification, isolation and characterization of process related impurities in ezetimibe.
Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
[TBL] [Abstract][Full Text] [Related]
39. Hyphenated HPLC-NMR and its applications in drug discovery.
Peng SX
Biomed Chromatogr; 2000 Oct; 14(6):430-41. PubMed ID: 11002280
[TBL] [Abstract][Full Text] [Related]
40. Characterization of stress degradation products of benazepril by using sophisticated hyphenated techniques.
Narayanam M; Sahu A; Singh S
J Chromatogr A; 2013 Jan; 1271(1):124-36. PubMed ID: 23237710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
